摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[2-(2,2,2-Trifluoroethoxy)pyridin-3-yl]methanamine | 771581-20-5

中文名称
——
中文别名
——
英文名称
[2-(2,2,2-Trifluoroethoxy)pyridin-3-yl]methanamine
英文别名
——
[2-(2,2,2-Trifluoroethoxy)pyridin-3-yl]methanamine化学式
CAS
771581-20-5
化学式
C8H9F3N2O
mdl
MFCD06212927
分子量
206.16
InChiKey
KUCFNEZLLQASNW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.375
  • 拓扑面积:
    48.1
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    (R)-(1H-benzo[d]imidazol-2-yl)-2-(4-methoxyphenyl)ethanamine dihydrochloride 、 [2-(2,2,2-Trifluoroethoxy)pyridin-3-yl]methanamine三氟乙酸 生成 (R)-1-(1-(1H-benzo[d]imidazol-2-yl)-2-(4-methoxyphenyl)ethyl)-3-((2-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)urea hydrochloride
    参考文献:
    名称:
    BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS
    摘要:
    本发明涉及公式(I)的苯并咪唑基甲基脲衍生物,其中n,D,E,R1,R2,R3,R4,R6,R7,R8和R9如说明书所定义,它们的制备以及它们作为药物活性化合物的用途。
    公开号:
    US20160200686A1
点击查看最新优质反应信息

文献信息

  • [EN] BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLYL-MÉTHYLURÉE EN TANT QU'AGONISTES DU RÉCEPTEUR ALX
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2015019325A1
    公开(公告)日:2015-02-12
    The present invention relates to benzimidazolyl-methyl urea derivatives of formula (I), wherein n, D, E, R1, R2, R3, R4, R6, R7, R8 and R9 are as defined in the description, their preparation and their use as pharmaceutically active compounds.
    本发明涉及式(I)的苯并咪唑基甲基生物,其中n、D、E、R1、R2、R3、R4、R6、R7、R8和R9如描述中所定义,它们的制备以及它们作为药用活性化合物的用途。
  • [EN] AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE<br/>[FR] ANALOGUES D'AMINO-TÉTRAZOLES ET MÉTHODES D'UTILISATION
    申请人:ABBOTT LAB
    公开号:WO2005111003A1
    公开(公告)日:2005-11-24
    A compound having Formula (I) or Formula (II) is disclosed as an P2X7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R1, R2, R3, R4, and R5, are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X7 are also disclosed.
    公开了具有化学式(I)或化学式(II)的化合物作为P2X7拮抗剂,其中A、B、C、Y、Y、Z、m、v、R1、R2、R3、R4和R5如描述中所定义。还公开了用于治疗受P2X7调节的疾病或症状的方法和组合物。
  • Pyrazole compounds and their use as antidiabetes agents
    申请人:Takagi Masaki
    公开号:US20070032529A1
    公开(公告)日:2007-02-08
    The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R 1 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group, R 2 represents a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or an azido group, R 3 represents a halogen atom, a hydroxyl group, a C 1-6 alkyl group, a halo C 1-6 alkyl group, a C 1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C 1-6 alkylsulfonylamino group, R 4 and R 5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C 1-6 alkyl group, a C 3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C 7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.
    本发明提供了一种具有肝糖原磷酸化酶抑制活性的吡唑化合物,用作糖尿病的治疗或预防剂,所述吡唑化合物由以下通用式(I)表示:其中环Q代表芳基或杂芳基,R1代表氢原子、卤原子、C1-6烷基或C1-6烷氧基,R2代表卤原子、C1-6烷基、C1-6烷氧基或偶氮基,R3代表卤原子、羟基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、偶氮基、基、酰胺基或C1-6烷基磺酰胺基,R4和R5彼此相同或不同,代表氢原子、取代或未取代的C1-6烷基、取代或未取代的C3-8环烷基、取代或未取代的饱和杂环基、取代或未取代的芳基、C7-14芳基烷基、杂芳基等,或其药理学上可接受的盐。
  • HETEROCYCLIC COMPOUND HAVING ANTI-HIV ACTIVITY
    申请人:Toyama Chemical Co., Ltd.
    公开号:EP2810944A1
    公开(公告)日:2014-12-10
    A heterocyclic compound represented by the general formula (in the formula, R1, R2 and R3 may be the same or different, and each represents a hydrogen atom, a halogen atom, or this general formula (X1-Y1-R4) (in the formula: X1 represents this general formula (NR5) (in the formula, R5 represents a hydrogen atom, etc.) or the like; Y1 represents an optionally substituted C1-6 alkylene group or the like; and R4 represents an optionally substituted aryl group or the like), and Z represents a nitrogen atom or this general formula (CR6) (in the formula, R6 represents a hydrogen atom, a halogen atom, or an optionally substituted C1-12 alkyl group or the like)), or a salt thereof, exhibits excellent anti-HIV activity and is useful as an anti-HIV agent.
    由一般公式表示的杂环化合物(在公式中,R1、R2和R3可以相同也可以不同,每个表示氢原子、卤原子或这一般式(X1-Y1-R4)(在公式中:X1表示这一般式(NR5)(在公式中,R5表示氢原子等)或类似物;Y1表示可选择地取代的C1-6烷基链或类似物;R4表示可选择地取代的芳基或类似物),Z表示氮原子或这一般式(CR6)(在公式中,R6表示氢原子、卤原子或可选择地取代的C1-12烷基链或类似物)),或其盐,表现出优异的抗HIV活性,并可用作抗HIV剂。
  • Amino-tetrazole analogues and methods of use
    申请人:Carroll A. William
    公开号:US20060052374A1
    公开(公告)日:2006-03-09
    A compound having Formula (I) or Formula (II) is disclosed as an P2X 7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R 1 , R 2 , R 3 , R 4 , and R 5 , are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X 7 are also disclosed.
    本文披露一种化合物,其化学式为(I)或(II),作为P2X7拮抗剂,其中A、B、C、Y、Y、Z、m、v、R1、R2、R3、R4和R5如描述中所定义。同时,本文还披露了治疗P2X7调节的疾病或病症的方法和组合物。
查看更多